Takeda’s H1 Profit Tumbles on Write-Down Tied to Trial Setbacks, Outlook Slashed

Takeda Pharmaceutical’s revenue for the first half of FY2023 increased by 6.4% year on year, but its operating profit saw a double-digit drop of 53.2% as it took write-downs linked to a pair of clinical trial setbacks. The company slashed...read more